Rubella (German Measles) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Rubella (German Measles) – Pipeline Review, H2 2017’, provides an overview of the Rubella (German Measles) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rubella (German Measles), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rubella (German Measles) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Rubella (German Measles)

The report reviews pipeline therapeutics for Rubella (German Measles) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Rubella (German Measles) therapeutics and enlists all their major and minor projects

The report assesses Rubella (German Measles) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Rubella (German Measles)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Rubella (German Measles)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Rubella (German Measles) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Beijing Minhai Biotechnology Co Ltd

Biological E Ltd

Cadila Healthcare Ltd

Daiichi Sankyo Co Ltd

GlaxoSmithKline Plc

Indian Immunologicals Ltd

Sinovac Biotech Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Rubella (German Measles) - Overview 6

Rubella (German Measles) - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 9

Products under Development by Companies 10

Products under Development by Universities/Institutes 11

Rubella (German Measles) - Therapeutics Assessment 12

Assessment by Route of Administration 12

Assessment by Molecule Type 14

Rubella (German Measles) - Companies Involved in Therapeutics Development 16

Beijing Minhai Biotechnology Co Ltd 16

Biological E Ltd 16

Cadila Healthcare Ltd 16

Daiichi Sankyo Co Ltd 17

GlaxoSmithKline Plc 17

Indian Immunologicals Ltd 18

Sinovac Biotech Ltd 18

Rubella (German Measles) - Drug Profiles 19

(measles + mumps + rubella + varicella) vaccine - Drug Profile 19

Product Description 19

Mechanism Of Action 19

R&D Progress 19

(measles + mumps + rubella) vaccine - Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

(measles + mumps + rubella) vaccine - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

(measles + mumps + rubella) vaccine - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

(measles + rubella + varicella) vaccine - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

(measles + rubella) vaccine - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

(measles + rubella) vaccine - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

(measles + rubella) vaccine - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

(measles + rubella) vaccine - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

(measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

rubella vaccine - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

VN-0102 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Rubella (German Measles) - Dormant Projects 31

Appendix 32

Methodology 32

Coverage 32

Secondary Research 32

Primary Research 32

Expert Panel Validation 32

Contact Us 32

Disclaimer 33

List of Tables

List of Tables

Number of Products under Development for Rubella (German Measles), H2 2017 7

Number of Products under Development by Companies, H2 2017 8

Number of Products under Development by Universities/Institutes, H2 2017 9

Products under Development by Companies, H2 2017 10

Products under Development by Universities/Institutes, H2 2017 11

Number of Products by Stage and Route of Administration, H2 2017 13

Number of Products by Stage and Molecule Type, H2 2017 15

Rubella (German Measles) – Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2017 16

Rubella (German Measles) – Pipeline by Biological E Ltd, H2 2017 16

Rubella (German Measles) – Pipeline by Cadila Healthcare Ltd, H2 2017 17

Rubella (German Measles) – Pipeline by Daiichi Sankyo Co Ltd, H2 2017 17

Rubella (German Measles) – Pipeline by GlaxoSmithKline Plc, H2 2017 18

Rubella (German Measles) – Pipeline by Indian Immunologicals Ltd, H2 2017 18

Rubella (German Measles) – Pipeline by Sinovac Biotech Ltd, H2 2017 18

Rubella (German Measles) – Dormant Projects, H2 2017 31

List of Figures

List of Figures

Number of Products under Development for Rubella (German Measles), H2 2017 7

Number of Products under Development by Companies, H2 2017 8

Number of Products by Routes of Administration, H2 2017 12

Number of Products by Stage and Routes of Administration, H2 2017 12

Number of Products by Molecule Types, H2 2017 14

Number of Products by Stage and Molecule Types, H2 2017 14

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports